{"id":"W4286298407","doi":"10.1200/jco.2022.40.16_suppl.11528","title":"A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Atezolizumab; Internal medicine; Oncology; Refractory (planetary science); Chondrosarcoma; Cancer; Gastroenterology; Surgery; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001061403,0.001086955,0.001566827,0.0003433926,0.0003144419,0.000721173,0.0007969395,0.001156717,0.003257179],"category_scores_gemma":[0.0006304891,0.0004879774,0.000929269,0.0002617632,0.0004283362,0.0004772709,0.000345936,0.001913262,0.0009450602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006537751,"about_ca_system_score_gemma":0.001699873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000888802,"about_ca_topic_score_gemma":0.002560933,"domain_scores_codex":[0.9997361,0.00009006599,0.00001738686,0.00004687375,0.00004186784,0.00006769998],"domain_scores_gemma":[0.9996166,0.00003816376,0.0000603148,0.00003243639,0.00003905359,0.0002133565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5145988,0.16852,0.01369034,0.001883746,0.001269921,0.001330994,0.0005640943,0.003304265,0.09555693,0.0006894125,0.008733382,0.1898581],"study_design_scores_gemma":[0.3741628,0.5993623,0.01407123,0.00004531011,0.0002835958,0.001081536,0.00007157094,0.001336395,0.003794658,0.000202537,0.005562553,0.00002541119],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986096,0.001868283,0.0008874185,0.0002904594,0.000144708,0.007029813,0.001219864,0.0001052452,0.002358334],"genre_scores_gemma":[0.9785327,0.002054597,0.002433752,0.001435726,0.0001673674,0.006836527,0.003483681,0.00003207804,0.00502355],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003257179,"threshold_uncertainty_score":0.01089638,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.135447407007734,"score_gpt":0.5229142548348268,"score_spread":0.3874668478270928,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}